162 related articles for article (PubMed ID: 30336708)
1. Optimal frontline management of mantle cell lymphoma: can we agree?
Tang C; Kuruvilla J
Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
[No Abstract] [Full Text] [Related]
2. High-dose cytarabine in mantle cell lymphoma.
Martin P
Clin Adv Hematol Oncol; 2015 Oct; 13(10):646-9. PubMed ID: 27058567
[No Abstract] [Full Text] [Related]
3. Clinical Management Updates in Mantle Cell Lymphoma.
Chen R; Sanchez J; Rosen ST
Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
[TBL] [Abstract][Full Text] [Related]
4. Point: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma: Where It Fits in the New Paradigm.
Goy A
Oncology (Williston Park); 2016 Dec; 30(12):1055-8, 1060. PubMed ID: 27987196
[No Abstract] [Full Text] [Related]
5. [Ten years progression-free survival obtained in a patient with mantle cell lymphoma].
Wysokińska E; Kolak A; Starosławska E; Kieszko D; Kamińska M; Surdyka D; Mocarska A; Burdan F
Pol Merkur Lekarski; 2015 May; 38(227):280-2. PubMed ID: 26039024
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
8. Mantle-cell lymphoma in the elderly: is it time to CHOP and change?
Farrell K; Rule S
Leuk Lymphoma; 2012 Oct; 53(10):1855-6. PubMed ID: 22616710
[No Abstract] [Full Text] [Related]
9. Optimal management of mantle cell lymphoma in the primary setting.
Tang C; Kuruvilla J
Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
[No Abstract] [Full Text] [Related]
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
11. Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma.
Pessach I; Petevi K; Gkirkas K; Stamouli M; Constantinou P; Rontogianni D; Dimitriadis G; Tsirigotis P
Leuk Lymphoma; 2016 Nov; 57(11):2702-4. PubMed ID: 26999270
[No Abstract] [Full Text] [Related]
12. Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma.
Janikova A; Mareckova A; Baumeisterova A; Krejci M; Supikova J; Salek D; Horky O; Tichy B; Hanke I; Pospisilova S; Moulis M; Mayer J
Leuk Lymphoma; 2014 Aug; 55(8):1935-8. PubMed ID: 24160848
[No Abstract] [Full Text] [Related]
13. Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
Dreyling M
Nat Rev Clin Oncol; 2015 Jul; 12(7):376-8. PubMed ID: 26011491
[No Abstract] [Full Text] [Related]
14. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
16. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by
Smith MR; Hong F; Li H; Gordon LI; Gascoyne RD; Paietta EM; Advani RH; Forero-Torres A; Horning SJ; Kahl BS
Leukemia; 2017 Feb; 31(2):517-519. PubMed ID: 27780968
[No Abstract] [Full Text] [Related]
17. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
[TBL] [Abstract][Full Text] [Related]
18. Syngeneic transplant in mantle cell lymphoma: a rare event and review of the literature.
Engman CA; Hill JM; Meehan KR
Clin Adv Hematol Oncol; 2009 May; 7(5):321-3. PubMed ID: 19521320
[No Abstract] [Full Text] [Related]
19. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
20. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
